Ameloblastoma: a clinical review and trends in management

AC McClary, RB West, AC McClary, JR Pollack… - European Archives of …, 2016 - Springer
Ameloblastoma is a rare odontogenic neoplasm of the mandible and maxilla, with multiple
histologic variants, and high recurrence rates if improperly treated. The current mainstay of …

Biology and management of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and malignant peripheral nerve sheath tumors: state of the art and …

BC Widemann, A Italiano - Journal of clinical oncology, 2018 - ascopubs.org
Undifferentiated pleomorphic sarcomas, myxofibrosarcomas, and malignant peripheral
nerve sheath tumors are characterized by complex genomic characteristics and aggressive …

[HTML][HTML] Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing

F Ducimetière, A Lurkin, D Ranchère-Vince… - PloS one, 2011 - journals.plos.org
Background The exact overall incidence of sarcoma and sarcoma subtypes is not known.
The objective of the present population-based study was to determine this incidence in a …

Comprehensive histologic analysis of ALK-rearranged lung carcinomas

A Yoshida, K Tsuta, H Nakamura, T Kohno… - The American journal …, 2011 - journals.lww.com
Abstract A subset (1% to 5%) of non-small-cell lung carcinomas harbors the EML4-ALK
fusion gene. Data from previous studies on the histomorphology of ALK-rearranged lung …

Patient‐derived xenografts for individualized care in advanced sarcoma

J Stebbing, K Paz, GK Schwartz, LH Wexler, R Maki… - Cancer, 2014 - Wiley Online Library
BACKGROUND Patients with advanced, metastatic sarcoma have a poor prognosis, and the
overall benefit from the few standard‐of‐care therapeutics available is small. The rarity of …

Grading of soft tissue sarcomas: from histological to molecular assessment

A Neuville, F Chibon, JM Coindre - Pathology, 2014 - Elsevier
Several histological grading systems for soft tissue sarcomas have been described since the
early 1980s. Their main objective is to select patients for adjuvant chemotherapy. Two …

[HTML][HTML] Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived …

T Murakami, AS Singh, T Kiyuna, SM Dry, Y Li… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Ewing's sarcoma is a rare and aggressive malignancy. In the present study, tumor from a
patient with a Ewing's sarcoma with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) …

The in ovo CAM-assay as a xenograft model for sarcoma

GML Sys, L Lapeire, N Stevens, H Favoreel… - JoVE (Journal of …, 2013 - jove.com
Sarcoma is a very rare disease that is heterogeneous in nature, all hampering the
development of new therapies. Sarcoma patients are ideal candidates for personalized …

Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression

BA Teicher, E Polley, M Kunkel, D Evans… - Molecular cancer …, 2015 - AACR
The diversity in sarcoma phenotype and genotype make treatment of this family of diseases
exceptionally challenging. Sixty-three human adult and pediatric sarcoma lines were …

[HTML][HTML] The FUS-DDIT3 interactome in myxoid liposarcoma

SE Jamie, S Colborne, CS Hughes, GB Morin… - Neoplasia, 2019 - Elsevier
Myxoid liposarcoma is a malignant lipogenic tumor that develops in deep soft tissues. While
local control rates are good, current chemotherapy options remain ineffective against …